Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
Status:
Completed
Trial end date:
2017-01-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, randomized clinical trial of etanercept and celecoxib
alone/combined treatment in effectiveness and safety on active ankylosing spondylitis (AS).
Subjects will be randomly assigned in a 1:1:1 ratio to one of the three groups (celexocib
200mg bid, etanercept 50mg qw, etanercept plus Celecoxib group) for 54 weeks. Primary
endpoints are the magnetic resonance imaging (MRI) Spondyloarthritis Research Consortium of
Canada (SPARCC) score of sacroiliac(SI) joint and spine, as well as the Assessment of
SpondyloArthritis International Society (ASAS)20 response rate at 52 weeks.